The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Amid new worries that legal copycats of the weight-loss drugs from Eli Lilly and Novo Nordisk could erode the market for the ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

Adults taking Zepbound lost 47% more weight on average than those taking Wegovy, according to clinical trial data from ...

US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...

Eli Lilly and Company (NYSE: LLY) today announced topline results from the SURMOUNT-5 phase 3b open-label randomized clinical ...

Obesity is one of the greatest public health issues facing the NHS and weight loss drugs, such as tirzepatide, are an important tool in helping people lose weight while also reducing the risk of other ...

Tirzepatide has been shown in clinical trials to be more effective than diet and exercise support alone, and when compared ...

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than ...

Tirzepatide provided a 47% greater relative weight loss compared to Wegovy ® (semaglutide). On average, tirzepatide led to a superior weight loss of 20.2% compared to 13.7% with Wegovy.